title: Who fares worse after liver transplantation? Impact of donor and recipient variables on outcome: data from a prospective study.
abstract: BACKGROUND
  Numerous donor and recipient risk factors influence survival after liver transplantation (LT).
  
  
  METHODS
  The aim of this study was to prospectively evaluate the effect of donor and recipient variables on 12-month patient and graft survival after LT. Five hundred forty-six patients underwent LT in a single center (2000-2010).
  
  
  RESULTS
  Bilirubin (P=0.006) and cold ischemia time (P=0.002) were predictive of graft loss at 12 months after LT. Model for End-Stage Liver Disease score ≥25 was associated with a lower 12-month graft survival than Model for End-Stage Liver Disease score <15 (P=0.02). Hepatitis C virus (HCV)-positive patients showed a lower survival than HCV-negative patients 12 months after LT (P=0.04), with serum sodium concentration (P=0.01) predictive for graft survival. Donor age demonstrated a trend of prediction (P=0.05) for HCV-positive patient survival. In hepatocellular carcinoma patients, donor age (P=0.02 and 0.02) and use of partial graft (P=0.01 and 0.02) were predictive of patient and graft survival at 12 months after LT.
  
  
  CONCLUSIONS
  Bilirubin and cold ischemia time are crucial for graft outcome post-LT. Survival in HCV-positive patients is lower than in HCV-negative recipients. Donor age and partial graft use are predictive of patient and graft survival in hepatocellular carcinoma patients.
authors.affiliation: Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Via Giustiniani 2, Padua, Italy.
authors.forename: Martina
authors.initials: M
authors.lastname: Gambato
authors.forename: Anna C
authors.initials: AC
authors.lastname: Frigo
authors.forename: Kryssia I
authors.initials: KI
authors.lastname: Rodríguez Castro
authors.forename: Marco
authors.initials: M
authors.lastname: Senzolo
authors.forename: Elena
authors.initials: E
authors.lastname: Nadal
authors.forename: Francesco
authors.initials: F
authors.lastname: D'Amico
authors.forename: Alessandro
authors.initials: A
authors.lastname: Vitale
authors.forename: Enrico
authors.initials: E
authors.lastname: Gringeri
authors.forename: Giacomo
authors.initials: G
authors.lastname: Zanus
authors.forename: Umberto
authors.initials: U
authors.lastname: Cillo
authors.forename: Francesco P
authors.initials: FP
authors.lastname: Russo
authors.forename: Patrizia
authors.initials: P
authors.lastname: Burra
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001663:Bilirubin / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000473:pathology; D058625:End Stage Liver Disease / Q000473:pathology; D005260:Female; D006085:Graft Survival; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007511:Ischemia; D016031:Liver Transplantation / Q000379:methods*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001663:Bilirubin